European breast cancer therapeutics market is estimated to grow significantly at a CAGR of around 8.8% during the forecast period. The market is mainly driven due to the high prevalence of breast cancer within European countries that include UK, Germany, Italy Spain and others.
Request a Free Sample of our Report on European Breast Cancer Therapeutics Market: https://www.omrglobal.com/request-sample/european-breast-cancer-therapeutics-market
These countries play a significant role in growth including awareness programs, the introduction of new treatment solutions and government expenditure on breast cancer diagnosis and treatment. The European Breast Cancer Coalition works to raise awareness of breast cancer. The European Commission launched European Commission Initiative on Breast Cancer (ECIBC) in 2012 to ensure that all breast cancer care processes are performed with quality and correctly in all citizens in Europe.
European breast cancer therapeutics market is segmented on the basis of therapy. The Therapy segment is further classified into chemotherapy, hormone therapy, targeted therapy, radiation therapy and others (surgery). Among all therapies, chemotherapy market held the largest market share in the European breast cancer therapeutics market. Chemotherapy is most used when cancer in the lymph nodes and irrespective of tumor size or menopausal status. Along with that it is used for the treatment of breast cancer in premenopausal women and referred for those women who diagnosed with early stage breast cancer for hormone receptor negative and HER2 positive cancer. The types of chemotherapy include adjuvant chemotherapy and neoadjuvant chemotherapy. The adjuvant chemotherapy is used to destroy cancer cells that have been spread and not seen by the imaging tests. This method helps in reducing the cancer cells that form a new tumor in the other place of the body. Adjuvant chemotherapy reduces the risk of breast cancer coming back. Neoadjuvant chemotherapy can be used to reduce the size of the tumor, so it can be removed with less widespread surgery.
The companies which are contributing to the growth of the European breast cancer therapeutics market include AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Mylan NV, Novartis International AG, F. Hoffmann-La Roche AG, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
A Full Report of European Breast Cancer Therapeutics Market is Available at https://www.omrglobal.com/industry-reports/european-breast-cancer-therapeutics-market
European Breast Cancer Therapeutics Market Segmentation
- Hormone Therapy
- Targeted Therapy
- Radiation Therapy
- Others (Surgery)
- Rest of Europe
- AbbVie Inc.
- AstraZeneca PLC
- Astellas Pharma Inc.
- Bayer AG
- GlaxoSmithKline PLC
- Mylan NV
- Merck & Co., Inc.
- Novartis International AG
- F. Hoffmann-La Roche AG
- Sanofi S.A.
For More Customized Data, Request for Report Customization @https://www.omrglobal.com/report-customization/european-breast-cancer-therapeutics-market
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit https://www.omrglobal.com/
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Contact no: +1 646-755-7667, +91 780-304-0404